WEX Pharmaceuticals Inc.

WEX Pharmaceuticals Inc.

October 02, 2007 19:54 ET

WEX Pharmaceuticals Inc.: Results of Post Hoc Analysis of Tectin™ Clinical Trial Accepted for Publication

VANCOUVER, BRITISH COLUMBIA--(Marketwire - Oct. 2, 2007) - WEX Pharmaceuticals Inc. ("WEX" or the "Company") (TSX:WXI) is pleased to announce that the post hoc analysis of its WEX-014 trial, "Tetrodotoxin for Moderate to Severe Cancer Pain: A Randomized, Double Blind, Parallel Design Multicenter Study" is in press in the peer reviewed Journal of Pain and Symptom Management.

The analysis of the data shows that based on the primary endpoint, pain intensity difference, there was a non-statistically significant trend toward more responders in the tetrodotoxin arm. However, using a composite endpoint evaluating decrease in pain outcome, and improvement in quality of life, the number of responders to tetrodotoxin was significantly greater than the number of responders to placebo.

Based on this analysis, the Company has designed a Phase III clinical trial (TEC-006). This multi-centre, randomized, double-blind, and placebo-controlled trial will include approximately 120 patients with moderate to severe cancer-related pain. WEX has received a No Objection Letter from Health Canada for this trial and pre-trial activities have commenced.

About WEX Pharmaceuticals Inc.

WEX Pharmaceuticals Inc. is dedicated to the discovery, development, manufacture and commercialization of innovative drug products to treat pain. The Company's principal business strategy is to derive drugs from naturally occurring toxins and develop proprietary products for the global market. The Company's Chinese subsidiary sells generic products manufactured at its facility in China.

Forward Looking Statements and Information

This News Release contains forward-looking statements which may not be based on historical fact. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, events or developments to be materially different from any future results, events or developments expressed or implied by such forward-looking statements. These factors should be considered carefully and readers are cautioned not to place undue reliance on such forward-looking statements. The company disclaims any obligation to update any such factors or to publicly announce the result of any revisions to any of the forward-looking statements contained herein to reflect future results, events or developments.

Contact Information